Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large cohort of AML patients, which facilitated discovery of functional genomic correlates. Here, we present a dataset that has been harmonized with our initial report to yield a cumulative cohort of 805 patients (942 specimens). We show strong cross-cohort concordance and identify features of drug response. Further, deconvoluting transcriptomic data shows that drug sensitivity is governed broadly by AML cell differentiation state, sometimes conditionally affecting other correlates of response. Finally, modeling of clinical outcome reveals a single gene, PEAR1, to be among the strongest predictors of patient survival, especially for young patients. Collectively, this report expands a large functional genomic resource, offers avenues for mechanistic exploration and drug development, and reveals tools for predicting outcome in AML.

Citing Articles

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Fiskus W, Mill C, Piel J, Collins M, Hentemann M, Cuglievan B Blood Cancer J. 2025; 15(1):40.

PMID: 40089460 DOI: 10.1038/s41408-025-01251-7.

The synergistic effect of c-Myb hyperactivation and Pu.1 deficiency induces Pelger-Huët anomaly and promotes sAML.

Xu S, Hong J, Dongye M, Lin J, Xue R, Huang Z Proc Natl Acad Sci U S A. 2025; 122(9):e2416121122.

PMID: 40020188 PMC: 11892618. DOI: 10.1073/pnas.2416121122.

Fusion oncoproteins and cooperating mutations define disease phenotypes in -rearranged leukemia.

Umeda M, Hiltenbrand R, Michmerhuizen N, Barajas J, Thomas M, Arthur B medRxiv. 2025; .

PMID: 39974131 PMC: 11838931. DOI: 10.1101/2025.01.21.25320683.

Machine learning-based bulk RNA analysis reveals a prognostic signature of 13 cell death patterns and potential therapeutic target of SMAD3 in acute myeloid leukemia.

Bao X, Chen Y, Chang J, Du J, Yang C, Wu Y BMC Cancer. 2025; 25(1):273.

PMID: 39955536 PMC: 11830216. DOI: 10.1186/s12885-025-13658-3.

An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemia.

Gurashi K, Wang Y, Amaral F, Spence K, Cant R, Yao C Cell Rep Med. 2025; 6(2):101933.

PMID: 39892394 PMC: 11866517. DOI: 10.1016/j.xcrm.2025.101933.

References

Fuller T, Ghazalpour A, Aten J, Drake T, Lusis A, Horvath S . Weighted gene coexpression network analysis strategies applied to mouse weight. Mamm Genome. 2007; 18(6-7):463-72. PMC: 1998880. DOI: 10.1007/s00335-007-9043-3. View

Scheib J, Sullivan C, Carter B . Jedi-1 and MEGF10 signal engulfment of apoptotic neurons through the tyrosine kinase Syk. J Neurosci. 2012; 32(38):13022-31. PMC: 3464495. DOI: 10.1523/JNEUROSCI.6350-11.2012. View

Krivtsov A, Rozov F, Zinovyeva M, Hendrikx P, Jiang Y, Visser J . Jedi--a novel transmembrane protein expressed in early hematopoietic cells. J Cell Biochem. 2007; 101(3):767-84. DOI: 10.1002/jcb.21232. View

Tyner J, Tognon C, Bottomly D, Wilmot B, Kurtz S, Savage S . Functional genomic landscape of acute myeloid leukaemia. Nature. 2018; 562(7728):526-531. PMC: 6280667. DOI: 10.1038/s41586-018-0623-z. View

Blucher A, McWeeney S, Stein L, Wu G . Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz. F1000Res. 2019; 8:908. PMC: 6644836. DOI: 10.12688/f1000research.19592.1. View

Wang Y, Lin C, Yao C, Hsu C, Hou H, Tsai C . A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. Blood Adv. 2020; 4(4):644-654. PMC: 7042996. DOI: 10.1182/bloodadvances.2019001185. View

Gentles A, Plevritis S, Majeti R, Alizadeh A . Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010; 304(24):2706-15. PMC: 4089862. DOI: 10.1001/jama.2010.1862. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

Falini B, Nicoletti I, Martelli M, Mecucci C . Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2006; 109(3):874-85. DOI: 10.1182/blood-2006-07-012252. View

10.

Kurtz S, Eide C, Kaempf A, Khanna V, Savage S, Rofelty A . Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017; 114(36):E7554-E7563. PMC: 5594650. DOI: 10.1073/pnas.1703094114. View

11.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

12.

Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R . Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020; 1(8):826-839. PMC: 7591155. DOI: 10.1038/s43018-020-0103-x. View

13.

Petersdorf S, Kopecky K, Slovak M, Willman C, Nevill T, Brandwein J . A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013; 121(24):4854-60. PMC: 3682338. DOI: 10.1182/blood-2013-01-466706. View

14.

H Elsayed A, Rafiee R, Cao X, Raimondi S, Downing J, Ribeiro R . A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia. 2019; 34(3):735-745. PMC: 7135934. DOI: 10.1038/s41375-019-0604-8. View

15.

Lewis J, Ryan K, OConnell J, Horenstein R, Damcott C, Gibson Q . Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013; 6(2):184-92. PMC: 3715320. DOI: 10.1161/CIRCGENETICS.111.964627. View

16.

Shen Z, Chen G, Ni J, Li X, Xiong S, Qiu Q . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89(9):3354-60. View

17.

Malani D, Kumar A, Bruck O, Kontro M, Yadav B, Hellesoy M . Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discov. 2021; 12(2):388-401. PMC: 9762335. DOI: 10.1158/2159-8290.CD-21-0410. View

18.

Majumder M, Leppa A, Hellesoy M, Dowling P, Malyutina A, Kopperud R . Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. Haematologica. 2019; 105(6):1527-1538. PMC: 7271564. DOI: 10.3324/haematol.2019.217414. View

19.

Izzi B, Pistoni M, Cludts K, Akkor P, Lambrechts D, Verfaillie C . Allele-specific DNA methylation reinforces PEAR1 enhancer activity. Blood. 2016; 128(7):1003-12. DOI: 10.1182/blood-2015-11-682153. View

20.

Johnson A, Yanek L, Chen M, Faraday N, Larson M, Tofler G . Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010; 42(7):608-13. PMC: 3057573. DOI: 10.1038/ng.604. View